PURPOSE: Lung cancer is the leading cause of cancer-related mortality among women. The role of hormone replacement therapy (HRT) in lung cancer development is unclear. PATIENTS AND METHODS: We evaluated a prospective cohort of 36,588 peri- and postmenopausal women aged 50 to 76 years from Washington State recruited in 2000 to 2002 (Vitamins and Lifestyle [VITAL] Study). Lung cancer cases (n = 344) were identified through the Seattle-Puget Sound Surveillance, Epidemiology, and End Results cancer registry during 6 years of follow-up. Hazard ratios (HRs) associated with use and duration of specific HRT formulations were calculated for total incident lung cancer, specific morphologies, and cancer by stage at diagnosis. RESULTS: After adjusting for smoking, age, and other potential confounders, there was an increased risk of incident lung cancer associated with increasing duration of estrogen plus progestin (E+P) use (HR = 1.27 for E+P use 1 to 9 years, 95% CI, 0.91 to 1.78; and HR = 1.48 for E+P use > or = 10 years, 95% CI, 1.03 to 2.12; P for trend = .03). There was no association with duration of unopposed estrogen use. Duration of E+P use was associated with an advanced stage at diagnosis (P for trend = .03). CONCLUSION: Use of E+P increased the risk of incident lung cancer in a duration-dependent manner, with an approximate 50% increased risk for use of 10 years or longer. These findings may be helpful for informing women of their risk of developing lung cancer and delineating important pathways involved in hormone metabolism and lung cancer.
PURPOSE:Lung cancer is the leading cause of cancer-related mortality among women. The role of hormone replacement therapy (HRT) in lung cancer development is unclear. PATIENTS AND METHODS: We evaluated a prospective cohort of 36,588 peri- and postmenopausal women aged 50 to 76 years from Washington State recruited in 2000 to 2002 (Vitamins and Lifestyle [VITAL] Study). Lung cancer cases (n = 344) were identified through the Seattle-Puget Sound Surveillance, Epidemiology, and End Results cancer registry during 6 years of follow-up. Hazard ratios (HRs) associated with use and duration of specific HRT formulations were calculated for total incident lung cancer, specific morphologies, and cancer by stage at diagnosis. RESULTS: After adjusting for smoking, age, and other potential confounders, there was an increased risk of incident lung cancer associated with increasing duration of estrogen plus progestin (E+P) use (HR = 1.27 for E+P use 1 to 9 years, 95% CI, 0.91 to 1.78; and HR = 1.48 for E+P use > or = 10 years, 95% CI, 1.03 to 2.12; P for trend = .03). There was no association with duration of unopposed estrogen use. Duration of E+P use was associated with an advanced stage at diagnosis (P for trend = .03). CONCLUSION: Use of E+P increased the risk of incident lung cancer in a duration-dependent manner, with an approximate 50% increased risk for use of 10 years or longer. These findings may be helpful for informing women of their risk of developing lung cancer and delineating important pathways involved in hormone metabolism and lung cancer.
Authors: A R Kristal; R E Patterson; M L Neuhouser; M Thornquist; D Neumark-Sztainer; C L Rock; M C Berlin; L Cheskin; P J Schreiner Journal: J Am Diet Assoc Date: 1998-11
Authors: Laura P Stabile; Autumn L Gaither Davis; Christopher T Gubish; Toni M Hopkins; James D Luketich; Neil Christie; Sydney Finkelstein; Jill M Siegfried Journal: Cancer Res Date: 2002-04-01 Impact factor: 12.701
Authors: Apar Kishor Ganti; Abe E Sahmoun; Amit W Panwalkar; Ketki K Tendulkar; Anil Potti Journal: J Clin Oncol Date: 2005-11-28 Impact factor: 44.544
Authors: Christopher G Slatore; Alyson J Littman; David H Au; Jessie A Satia; Emily White Journal: Am J Respir Crit Care Med Date: 2007-11-07 Impact factor: 21.405
Authors: Matthew B Schabath; Xifeng Wu; Rena Vassilopoulou-Sellin; Ara A Vaporciyan; Margaret R Spitz Journal: Clin Cancer Res Date: 2004-01-01 Impact factor: 12.531
Authors: Gerardo Heiss; Robert Wallace; Garnet L Anderson; Aaron Aragaki; Shirley A A Beresford; Robert Brzyski; Rowan T Chlebowski; Margery Gass; Andrea LaCroix; JoAnn E Manson; Ross L Prentice; Jacques Rossouw; Marcia L Stefanick Journal: JAMA Date: 2008-03-05 Impact factor: 56.272
Authors: Vei Mah; Diana Marquez; Mohammad Alavi; Erin L Maresh; Li Zhang; Nam Yoon; Steve Horvath; Lora Bagryanova; Michael C Fishbein; David Chia; Richard Pietras; Lee Goodglick Journal: Lung Cancer Date: 2011-04-20 Impact factor: 5.705
Authors: Susan E Olivo-Marston; Leah E Mechanic; Steen Mollerup; Elise D Bowman; Alan T Remaley; Michele R Forman; Vidar Skaug; Yun-Ling Zheng; Aage Haugen; Curtis C Harris Journal: Carcinogenesis Date: 2010-08-20 Impact factor: 4.944
Authors: Nadiyah Kazmi; Diana C Márquez-Garbán; Lilia Aivazyan; Nalo Hamilton; Edward B Garon; Lee Goodglick; Richard J Pietras Journal: Lung Cancer Manag Date: 2012-12
Authors: Louise A Brinton; Lauren Schwartz; Margaret R Spitz; Yikyung Park; Albert R Hollenbeck; Gretchen L Gierach Journal: Cancer Causes Control Date: 2012-02-25 Impact factor: 2.506